Literature DB >> 2672254

Use of quinolones in chlamydial infection.

J D Oriel1.   

Abstract

The activity of fluoroquinolones against Chlamydia trachomatis has been studied in vitro. Those agents with an MIC of less than 2.0 mg/L may be of clinical value, and clinical trials have been conducted with ciprofloxacin, ofloxacin, and fleroxacin. Ciprofloxacin has given variable results in the treatment of Chlamydia-positive urethritis in men; some studies have shown an unacceptably high reisolation of the organisms with prolonged posttreatment surveillance. Ofloxacin may be an effective drug for the treatment of lower genital tract infections with C. trachomatis in men and women, and there are indications that ofloxacin may also be of value in the treatment of chlamydial epididymitis and salpingitis. Early studies of fleroxacin suggest that this drug may also be an effective antichlamydial agent.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2672254     DOI: 10.1093/clinids/11.supplement_5.s1273

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  4 in total

1.  In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogens.

Authors:  J Segreti; D J Hirsch; A A Harris; K S Kapell; H Orbach; H A Kessler
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 2.  Chlamydiae as pathogens--an overview of diagnostic techniques, clinical features, and therapy of human infections.

Authors:  A Oehme; P B Musholt; K Dreesbach
Journal:  Klin Wochenschr       Date:  1991-08-01

Review 3.  Chlamydial infections and the quinolones.

Authors:  A R Ronald; R W Peeling
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

4.  Study of the cytotoxic/toxic potential of the novel anticancer selenodiazoloquinolone on fibroblast cells and 3D skin model.

Authors:  Soňa Jantová; Dominika Topoľská; Michaela Janošková; Miroslav Pánik; Viktor Milata
Journal:  Interdiscip Toxicol       Date:  2017-05-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.